-
-
-
-
-
-
-
Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets
-
-
-
-
-
-
-
Ligand to acquire XOMA Royalty for $739 million in cash deal
-
-
-
-
-
-
-
Benchmark Reiterates Buy Rating on Ligand Pharma (LGND) Following Strong Forecasts for 2025/26
-
-
-
-
-
-
-
Ligand Pharma (LGND) Tops Q2 EPS by 17c ; Offers Guidance
-
-
-
-
-
-
-
Ligand Reports First Quarter 2025 Financial Results
-
-
-
-
-
-
-
Ligand Pharma (LGND) Introduces 2025 Guidance
-
-
-
-
-
-
-
Ligand Pharma (LGND) PT Raised to $140 at Craig-Hallum
-
1,219,404 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

